### PATENT COOPERATION TREATY

## **PCT**

# TRANSLATION INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 664316		FOR FURTHER ACT	TION	See Form PCT/IPEA/416		
International application No. PCT/JP2004/001617			1617	International filing date (	day/month/year)	Priority date (day/month/year)
	International Patent Classification (IPC) or national classification and IPC  A61K31/616 (2006.01), A61K9/06 (2006.01), A61K9/70 (2006.01), A61P17/00 (2006.01), A61P17/02 (2006.01), A61P17/04 (2006.01)					
	Applicant TEIKOKU SEIYAKU CO., LTD.					
1.				ninary examination report e applicant according to A		International Preliminary Examining Authority
2.	This R	EPORT consis	ts of a total of	6	sheets, including	g this cover sheet.
3.	This re	port is also acc	ompanied by A	NNEXES, comprising:		
	a	sent to th	e applicant and	to the International Burea	u) a total of	sheets, as follows:
		shee				amended and are the basis for this report and/or ale 70.16 and Section 607 of the Administrative
	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyon the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplementa Box.					
	b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))			r of electronic carrier(s))		
	, containing a sequence listing and/or table			_ , containing a sequence listing and/or tables		
related thereto, in computer a Section 802 of the Administra				-	dicated in the Supple	mental Box Relating to Sequence Listing (see
4.	This re	port contains i	ndications relati	ng to the following items:		
	$\boxtimes$	Box No. I	Basis of the	report		
		Box No. II	Priority			
	$\boxtimes$	Box No. III	Non-establi	shment of opinion with regard to novelty, inventive step and industrial applicability		
		Box No. IV	Lack of unit	ty of invention		
	BON 110. 1		atement under Article 35(2) with regard to novelty, inventive step or industrial applicability; I explanations supporting such statement			
		Box No. VI	Certain doc	uments cited		
		Box No. VII	Certain defe	ects in the international app	olication	
		Box No. VIII	Certain obse	ervations on the internation	nal application	
Date of submission of the demand		Da	te of completion of the	is report		
Name ar	Name and mailing address of the IPEA/JP		Au	Authorized officer		
Faccionil	la No			Ta	Talanhara Ma	
Facsimile No.		Te	lephone No.			

International application No.

PCT/JP2004/001617

Box	No. I	I Basis of the report		
1.		h regard to the language, this report is based on the internationated under this item.	onal application in the language in which	n it was filed, unless otherwise
		This report is based on translations from the original langum which is the language of a translation furnished for the pure international search (Rule 12.3 and 23.1(b))  publication of the international application (Rule 12.3 and 12.4 international preliminary examination (Rule 55.2 and 14.4 the absorber of the international preliminary examination).	4) 4/or 55.3)	,
2.	rece	h regard to the <b>elements</b> of the international application, this elving Office in response to an invitation under Article 14 a report):  the international application as originally filed/furnished the description:  pages		illy filed" and are not annexed to
		pages*		
		pages*		·
	П			
	ш	the claims:		os oviginally filed/frynished
		nos.		as originally filed/furnished
		nos.*	<del></del>	
		nos.*		
	$\Box$	nos.*	received by this Authority on	
	ш	the drawings:		
		sheets		as originally filed/furnished
		sheets*		
	$\overline{}$	sheets*	received by this Authority on	
	닏	a sequence listing and/or any related table(s) – see Suppler	nental Box Relating to Sequence Listing	
3.	Ш	The amendments have resulted in the cancellation of:		
		the description, pages		
		the claims, nos.		
		the drawings, sheets/figs		
		the sequence listing (specify):		
		any table(s) related to sequence listing (specify):		
4.		This report has been established as if (some of) the amen they have been considered to go beyond the disclosure as f	dments annexed to this report and listed	I below had not been made, since
		the description, pages		
		the claims, nos.		
		the drawings, sheets/figs		
		the sequence listing (specify):		
		any table(s) related to sequence listing (specify):		
*	If ite	em 4 applies, some or all of those sheets may be marked "sup	perseded."	

International application No.
PCT/JP2004/001617

Box No. II	II Non-establishment of opinion	n with regard to novelty, inventive step and industrial ap	plicability
	ions whether the claimed invention ap have not been examined in respect of:	opears to be novel, to involve an inventive step (to be no	on obvious), or to be industrially
	the entire international application		
	claims Nos. 8-12		
becaus	e:		
	the said international application, or the relate to the following subject matter w	e said claims Nos. 8-12 which does not require an international preliminary examinati	on (specify):
	The subject :	matter of claims 8 to 12 re	lates to
	methods for treat	ment of the human body by s	urgery or
	therapy, as well	as diagnostic methods. Thus	, this
	International Pre	liminary Examining Authorit	y is not
	required to carry	out international prelimin	ary
	examination on th	is subject matter under the	
	provisions of PCT	Rule 67.1(iv).	
	the description, claims or drawings (inn are so unclear that no meaningful opinion)	dicate particular elements below) or said claims Nosion could be formed (specify):	
$\boxtimes$	the claims, or said claims Nos. 8-1 by the description that no meaningful c		are so inadequately supported
	no international search report has been	established for said claims Nos.	
	the nucleotide and/or amino acid seque Instructions in that:	ence listing does not comply with the standard provided for	in Annex C of the Administrative
	the written form	has not been furnished does not comply with the standard	
	the computer readable form	has not been furnished does not comply with the standard	
		d/or amino acid sequence listing, if in computer readable for Annex C-bis of the Administrative Instructions.	orm only, do not comply with the
	See Supplemental Box for further deta-	ils.	

International application No.	
PCT/JP2004/001617	

Box		Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1.	Statement					
	Novelty (N)	Claims		YES		
		Claims	1-7	NO		
	Inventive step (IS)	Claims		YES		
		Claims	1-7	NO		
	Industrial applicabilit	y (IA) Claims	1-7	YES		
		Claims		NO		

- 2. Citations and explanations (Rule 70.7)
  - Document 1: JP 3-72426 A (Teikoku Seiyaku Co., Ltd.), 27

    March 1991
  - Document 2: EP 1249239 Al (Teikoku Seiyaku Co., Ltd.), 16
    October 2002
  - (i) The invention set forth in claims 1 to 7 lacks novelty and does not involve an inventive step in the light of document 1 cited in the international search report.

Document 1 sets forth an aspirin-containing ointment composition for treatment of neuralgic pain, containing 0.5wt% to 5wt% aspirin (claim 1). In addition, zoster and the like are given as symptoms of neuralgic pain (page 1, right column, lines 1 to 9).

(ii) The invention set forth in claims 1 to 7 lacks novelty and does not involve an inventive step in the light of document 2 cited in the international search report.

Document 2 sets forth a antipruritic agents for external use, containing acetylsalicylic acid (claim 1). Document 2 also indicates that the quantity of aspirin contained falls within the range of 0.05wt% to 80wt%

International application No.
PCT/JP2004/001617

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

(paragraph [0014]).

Moreover, although document 2 does not indicate that said antipruritic agents for external use are used for the treatment of skin and mucosal injuries caused by viral infection, the invention set forth in document 2 is used in dermatitis and eczema as antipruritic agents for external use, therefore even if the term "by viral infection" is used to specify the invention, it is impossible to make a clear distinction between the invention set forth in claims 1 to 7 of this application and the invention set forth in document 2.

International application No.
PCT/JP2004/001617

Supplemental Box
In case the space in any of the preceding boxes is not sufficient.  Continuation of: Front page
A61P29/00(2006.01)